Business
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
DUBLIN--(BUSINESS WIRE)-- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational
About this update from Prothena Corporation Plc
[{"type":"text","content":" DUBLIN--(BUSINESS WIRE)--\nProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced partner presentations on clinical updates from prasinezumab for the treatment of Parkinson’s disease and BMS-986446 for the treatment of Alzheimer’s disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) in Copenhagen, Denmark, and online.\n\n\nRoche Presentations on Prasinezumab for the Potential Treatment of Parkinson’s Disease\n\n\nIndustry Symposium – Pathways to Progress: Exploring Innovations in AD and PD for Future Practice\n\n\n\nChair: Malú G. Tansey, Ph.D., Indiana University School of Medicine Stark Neuroscience Institute\n\n\n\nDate: Tuesday March 17, 2026\n\n\n\nThis symposium reviewed the evolving understanding of the molecular pathophysiology and disease heterogeneity across Alzheimer's disease (AD) and Parkinson's disease (PD). Explored current and emerging treatment pathways, e.g. alpha-synuclein, amyloid-beta and neuroinflammation; including diagnostics, biomarkers and therapeutics. Considered how the advancing understanding of AD and PD informs innovative clinical development approaches and clinical practice.\n\n\nOral Presentation – Modeling Parkinson’s Disease Progression to Quantify Long-Term Treatment Effects via the Concept of ‘Time Saved’\n\n\n\nPresenter: Benjamin Ribba, Roche\n\n\n\nDate: Thursday March 19, 2026\n\n\n\nThe comparison of PASADENA open-label extension (OLE) data with PPMI-based model predictions supports potential disease-modifying efficacy with an estimated two years of ‘time saved’ providing an intuitive measure of long-term benefit. The observed PASADENA OLE outcomes consistently deviated from the model-predicted progression, suggesting a sustained treatment effect. On average, participants were approximately two years less advanced in disease severity five years after the start of the trial compared to the virtual comparator.\n\n\nOral Presentation – Prasinezumab in Early-Stage Parkinson’s Disease: Additional Data from the PADOVA Study\n\n\n\nPresenter: Tania Nikolcheva, M.D., Ph.D., Roche\n\n\n\nDate: Saturday March 21, 2026\n\n\n\nLonger term data from the PADOVA OLE study in early-stage ...